Can you take Peginterferon alfa-2a with Rex Paracetamol?

The acetaminophen in Rex Paracetamol has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

Peginterferon alfa-2a has a major potential interaction with Autoimmune Disorders.

Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis. Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.

Peginterferon alfa-2a has a major potential interaction with Autoimmune Hepatitis.

The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.

Peginterferon alfa-2a has a major potential interaction with Cardiovascular Conditions and Disorders.

Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.

Peginterferon alfa-2a has a major potential interaction with Cirrhosis.

The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.

The acetaminophen in Rex Paracetamol has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Peginterferon alfa-2a has a major potential interaction with Depression.

Life-threatening or fatal neuropsychiatric reactions have been reported in patients receiving peginterferons alfa, including suicide, suicide ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose. These reactions have occurred in patients with and without previous psychiatric illness. These drugs should be used with extreme caution in patients with a history of depression. Other events reported include aggressive behavior, psychosis, hallucinations, bipolar disorder and mania. Patients should be monitored for any evidence of depression or other psychiatric symptoms, and they should be advised to report any signs or symptoms of depression or other changes in mood or behavior. In severe cases, therapy should be stopped immediately and psychiatric intervention should be instituted.

Peginterferon alfa-2a has a moderate potential interaction with Diabetes Mellitus.

Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus. Treatment should be administered with caution on patients with these conditions. Treatment should not be initiated if the condition cannot be effectively treated by medication. Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.

Peginterferon alfa-2a has a major potential interaction with HIV-1 Infection.

The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.

Peginterferon alfa-2a has a moderate potential interaction with Hyperthyroidism.

Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus. Treatment should be administered with caution on patients with these conditions. Treatment should not be initiated if the condition cannot be effectively treated by medication. Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.

Peginterferon alfa-2a has a moderate potential interaction with Hypoglycemia.

Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus. Treatment should be administered with caution on patients with these conditions. Treatment should not be initiated if the condition cannot be effectively treated by medication. Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.

The acetaminophen in Rex Paracetamol has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The acetaminophen in Rex Paracetamol has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Peginterferon alfa-2a has a moderate potential interaction with Neutropenia.

Peginterferons alfa suppress bone marrow function and may result in severe cytopenias. Very rarely, it may be associated with aplastic anemia. These drugs should be used with caution in patients with baseline neutrophil counts less than 1,500 cells/mm3, with platelet counts less than 90,000 cells/mm3 or baseline hemoglobin less than 10 g/dL. It is advised that complete blood counts be obtained pretreatment and monitored routinely during therapy. Neutropenia and thrombocytopenia occur with greater incidence in patients coinfected with HIV.

The acetaminophen in Rex Paracetamol has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

Peginterferon alfa-2a has a moderate potential interaction with Pulmonary Impairment.

Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy. Caution should be used when used in patients with preexisting pulmonary disorders.

Peginterferon alfa-2a has a major potential interaction with Renal Dysfunction.

Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).

Peginterferon alfa-2a has a moderate potential interaction with Thrombocytopenia.

Peginterferons alfa suppress bone marrow function and may result in severe cytopenias. Very rarely, it may be associated with aplastic anemia. These drugs should be used with caution in patients with baseline neutrophil counts less than 1,500 cells/mm3, with platelet counts less than 90,000 cells/mm3 or baseline hemoglobin less than 10 g/dL. It is advised that complete blood counts be obtained pretreatment and monitored routinely during therapy. Neutropenia and thrombocytopenia occur with greater incidence in patients coinfected with HIV.

Peginterferon alfa-2a has a moderate potential interaction with Underactive Thyroid.

Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus. Treatment should be administered with caution on patients with these conditions. Treatment should not be initiated if the condition cannot be effectively treated by medication. Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.

Peginterferon alfa-2a has a moderate potential interaction with Visual Defect/Disturbance.

Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons. All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders. Patients should have periodic ophthalmologic exams during treatment.